特布他林雾化吸入治疗慢性阻塞性肺疾病效果评价.doc

特布他林雾化吸入治疗慢性阻塞性肺疾病效果评价 　　[摘要]目的 探讨特布他林雾化吸入治疗慢性阻塞性肺疾病（COPD）的临床疗效。方法 选取2015年1月～2016年12月我院收治的60例COPD急性期患者，采用数字表法随机分组，对照组30例采用布地奈德雾化吸入治疗，研究组30例则在对照组基础上加用特布他林，两组患者均连续用药1周，治疗结束后评价疗效并比较患者用力肺活量（FVC）、一秒呼气容积（FEV1）、用力呼气量占用力肺活量比值（FEV1/FVC）等肺功能改善情况。结果 研究组总有效率为96.7%（29/30），对照组总有效率为80.0%（24/30），差异有统计学意义（P0.05），治疗后研究组均显著优于对照组，差异有统计学意义（P0.05）。结论 特布他林联合布地奈德雾化吸入治疗急性期COPD的疗效要明显优于单纯应用布地奈德，可有效改善患者的肺功能，值得在临床上推广和应用。 　　[关键词]慢性阻塞性肺疾病；特布他林；布地奈德；雾化吸入 　　[中图分类号] R725.6 [文献标识码] A [文章编号] 1674-4721（2017）06（a）-0039-03 　　[Abstract]Objective To investigate the clinical efficacy of Terbutaline inhalation therapy for chronic obstructive pulmonary disease （COPD）.Methods 60 patients with acute COPD were enrolled in our hospital from January 2015 to December 2016， randomized by digital table method， and 30 patients in the control group were treated with inhalation of budesonide，30 patients in the study group were treated with control group based on the use of Terbutaline， the two groups of patients were treated for 1 week， after the end of treatment to evaluate the efficacy and improve the patient′s lung function improvement. Results The total effective rate was 96.7%（29/30） in the study group and 80.0%（24/30） in the control group， the difference was statistically significant（P0.05）. After treatment，the study group for the indexes above were significantly better than those in the control group，the differences were statistically significant （P0.05）.Conclusion The efficacy of Terbutaline combined with Budesonide inhalation in the treatment of acute chronic obstructive pulmonary disease is superior to that of Budesonide alone， which can effectively improve the pulmonary function of patients and is worthy of clinical application and promotion. 　　[Key words]Chronic obstructive pulmonary disease；Terbutaline； Budesonide；Aerosol inhalation 　　慢性阻塞性肺疾病（COPD）是常见呼吸道疾病，患者表现为不完全的气流受限，具有一定的可逆性[1]，急性发作期会导致患者的肺功能明显降低，患者出现明显的喘息、咳嗽、呼吸不畅等症状，COPD是导致多种呼吸道和心血管并发症的重要因素，严重影响患者的健康[2-3]。随着雾化吸入治疗在临床上的普及，COPD患者的预后逐渐改善，本文就特布他林雾化